HT-VA outperformed Danish drug Novo Nordisk’s blockbuster semaglutide drug in key gene expression markers tied to liver fat regulation, the company said. ・The company is now looking to advance the ...

In the open-label PK cohort, 100% of evaluable patients achieved clinical response by Week 6, accompanied by an approximate 50% reduction in investigator-assessed disease severity (using the ARIGA ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted under its Cooperative Research and Development ...

NEW YORK, April 12, 2021 /PRNewswire/ — Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, together with its manufacturing partner, has successfully completed ...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Hoth Therapeutics HOTH is a clinical-stage ...

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a ...

Patients will be able to enroll in trial at any time and regardless of failure from other therapeutics This is a randomized, double-blind, placebo-controlled, multi-center Phase 2a dose-ranging study ...

CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patients With No Current FDA-Approved Treatment Option NEW YORK, Feb. 24, 2026 /PRNewswire/ -- Hoth ...

Detailed price information for Hoth Therapeutics Inc (HOTH-Q) from The Globe and Mail including charting and trades.